Cancer Research

Cancer is a term used to define a group of diseases in which abnormal cells divide without control, are able to invade neighboring tissues/organs and metastasize. Cancer has been characterized by six hallmarks; self sufficiency in proliferative growth signals, insensitivity to growth inhibitors, evasion of apoptosis, limitless replicative potential, ability to develop blood vessels (angiogenesis), and tissue invasion and metastasis.

Cancer Research Products Areas

Products for Cancer Research - Page 42

Cat.No. Product Name Information/Activity
BCC4039 XL413 hydrochloride Potent and selective Cdc7 inhibitor,XL413 (BMS-863233) is a potent and selective cell division cycle 7 homolog (CDC7) kinase inhibitor with IC50 of 3.4 nM, showing 63-, 12- and 35-fold selectivity over CK2, Pim-1 and pMCM2, respectively. Phase 1/2.
BCC7912 YC 1 Lificiguat binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO.
BCC1389 AZ20 AZ20 is a potent and selective inhibitor of ATR with an IC50 of 5 nM, and has 8-fold selectivity against mTOR (IC50=38 nM).
BCC3731 AZ3146 AZ3146 is a reasonably potent and selective Mps1 inhibitor with IC50 of 35 nM for Mps1Cat.
BCC7622 Compound 401 Compound 401 is a synthetic inhibitor of DNA-PK (IC50 = 0.28 μM) that also targets mTOR but not PI3K in vitro.
BCC7259 DMNB 20357-25-9
BCC2475 KU 55933 KU-55933 is a potent ATM inhibitor with an IC50 and Ki of 12.9 and 2.2 nM, respectively, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
BCC5986 Mirin Mirin is a small-molecule inhibitor of MRN (Mre11, Rad50, and Nbs1) complex.
BCC7540 NSC 109555 ditosylate 66748-43-4
BCC3933 NU 7026 NU 7026 (LY293646) is a novel specific DNA-PK inhibitor with IC50 of 0.23 μM, also inhibits PI3K with IC50 of 13 μM.